JP2022514420A5 - - Google Patents
Info
- Publication number
- JP2022514420A5 JP2022514420A5 JP2021535804A JP2021535804A JP2022514420A5 JP 2022514420 A5 JP2022514420 A5 JP 2022514420A5 JP 2021535804 A JP2021535804 A JP 2021535804A JP 2021535804 A JP2021535804 A JP 2021535804A JP 2022514420 A5 JP2022514420 A5 JP 2022514420A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide sequence
- promoter
- cancer
- operably linked
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862784372P | 2018-12-21 | 2018-12-21 | |
| US62/784,372 | 2018-12-21 | ||
| US201962872699P | 2019-07-10 | 2019-07-10 | |
| US62/872,699 | 2019-07-10 | ||
| US201962930524P | 2019-11-04 | 2019-11-04 | |
| US62/930,524 | 2019-11-04 | ||
| PCT/CA2019/051898 WO2020124273A1 (en) | 2018-12-21 | 2019-12-20 | Modified orthopoxvirus vectors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022514420A JP2022514420A (ja) | 2022-02-10 |
| JP2022514420A5 true JP2022514420A5 (enExample) | 2023-01-04 |
Family
ID=71100021
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535804A Pending JP2022514420A (ja) | 2018-12-21 | 2019-12-20 | 修飾オルソポックスウイルスベクター |
| JP2021535833A Pending JP2022516006A (ja) | 2018-12-21 | 2019-12-20 | 修飾オルソポックスウイルスベクター |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535833A Pending JP2022516006A (ja) | 2018-12-21 | 2019-12-20 | 修飾オルソポックスウイルスベクター |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20220056480A1 (enExample) |
| EP (2) | EP3898997A4 (enExample) |
| JP (2) | JP2022514420A (enExample) |
| KR (2) | KR20210132003A (enExample) |
| CN (2) | CN113661246A (enExample) |
| AU (2) | AU2019404639A1 (enExample) |
| BR (2) | BR112021012078A2 (enExample) |
| CA (2) | CA3124301A1 (enExample) |
| CL (1) | CL2021001646A1 (enExample) |
| CO (1) | CO2021009354A2 (enExample) |
| EC (1) | ECSP21053474A (enExample) |
| IL (2) | IL284180A (enExample) |
| MX (2) | MX2021007438A (enExample) |
| PE (1) | PE20212307A1 (enExample) |
| PH (1) | PH12021551436A1 (enExample) |
| SG (1) | SG11202106460XA (enExample) |
| TW (1) | TW202039851A (enExample) |
| WO (2) | WO2020124273A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10612005B2 (en) | 2016-01-08 | 2020-04-07 | Replimune Limited | Modified oncolytic virus |
| JP7724601B2 (ja) | 2017-02-03 | 2025-08-18 | ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 腫瘍溶解性ウイルス療法 |
| SG11202006457YA (en) | 2018-01-05 | 2020-08-28 | Ottawa Hospital Res Inst | Modified orthopoxvirus vectors |
| EP4061417A4 (en) * | 2019-11-20 | 2023-10-11 | University of Pittsburgh - of the Commonwealth System of Higher Education | VACCINIA VIRUSES AND METHOD FOR USING VACCINIA VIRUSES |
| JP6915792B1 (ja) * | 2020-10-01 | 2021-08-04 | 国立大学法人鳥取大学 | 広範囲遺伝子欠損を有する腫瘍溶解性ワクシニアウイルス |
| WO2023106839A1 (ko) * | 2021-12-07 | 2023-06-15 | 재단법인 아산사회복지재단 | Il-12를 발현하는 재조합 백시니아 바이러스 및 이의 용도 |
| JP2025503721A (ja) * | 2022-01-17 | 2025-02-04 | ノイスコム アーゲー | がん治療用免疫刺激タンパク質をコードする組換えオルソポックスウイルスベクター |
| CN119677861A (zh) * | 2022-06-10 | 2025-03-21 | 特兰斯吉恩股份有限公司 | 表达白介素-12的重组病毒 |
| IL318055A (en) * | 2022-07-08 | 2025-02-01 | Viromissile Inc | ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF |
| CN119923267A (zh) * | 2022-07-27 | 2025-05-02 | 阿斯利康(瑞典)有限公司 | 表达白介素-12的重组病毒与pd-1/pd-l1抑制剂的组合 |
| CN115947797B (zh) * | 2022-08-02 | 2024-07-05 | 青岛硕景生物科技有限公司 | 猴痘病毒重组抗原及其应用 |
| WO2024130212A1 (en) | 2022-12-16 | 2024-06-20 | Turnstone Biologics Corp. | Recombinant vaccinia virus encoding one or more natural killer cell and t lymphocyte inhibitors |
| CN116200349A (zh) * | 2023-01-18 | 2023-06-02 | 中国医学科学院病原生物学研究所 | 一种基于改良痘苗病毒天坛株的新型冠状病毒疫苗 |
| CN115927215B (zh) * | 2023-01-18 | 2025-10-17 | 中国医学科学院病原生物学研究所 | 一种定向减毒的痘苗病毒疫苗 |
| CN118240879A (zh) * | 2023-11-01 | 2024-06-25 | 上海市重大传染病和生物安全研究院 | 骨架质粒、重组质粒以及猴痘病毒颗粒和应用 |
| WO2026047314A1 (en) * | 2024-08-28 | 2026-03-05 | University Of Surrey | Recombinant vector |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2150495T5 (es) * | 1993-05-19 | 2007-02-16 | Schering Corporation | Ligandos de flt3 purificados de mamifero y agonistas y antagonistas de los mismos. |
| KR20120002613A (ko) * | 2002-08-12 | 2012-01-06 | 제네렉스, 인코포레이티드 | 폭스바이러스 및 암과 관련된 방법 및 조성물 |
| AU2003290528A1 (en) * | 2002-10-15 | 2004-05-04 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Methods and reagents for inducing immunity |
| RU2503717C2 (ru) * | 2007-11-19 | 2014-01-10 | Трансжене Са | Поксвирусные онколитические векторы |
| RS65104B1 (sr) * | 2013-08-22 | 2024-02-29 | Univ Pittsburgh Commonwealth Sys Higher Education | Onkolitičke imunoterapije |
| RU2696312C2 (ru) * | 2014-07-16 | 2019-08-01 | Трансген Са | Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек |
| CN106520778A (zh) * | 2015-09-09 | 2017-03-22 | 北京锤特生物科技有限公司 | 改造的白介素12及其在制备治疗肿瘤的药物中的用途 |
| WO2018049248A1 (en) * | 2016-09-09 | 2018-03-15 | Icellhealth Consulting Llc | Oncolytic virus equipped with bispecific engager molecules |
| SG11202006457YA (en) * | 2018-01-05 | 2020-08-28 | Ottawa Hospital Res Inst | Modified orthopoxvirus vectors |
-
2019
- 2019-12-20 EP EP19898487.4A patent/EP3898997A4/en not_active Withdrawn
- 2019-12-20 TW TW108147116A patent/TW202039851A/zh unknown
- 2019-12-20 AU AU2019404639A patent/AU2019404639A1/en not_active Abandoned
- 2019-12-20 KR KR1020217022872A patent/KR20210132003A/ko not_active Ceased
- 2019-12-20 MX MX2021007438A patent/MX2021007438A/es unknown
- 2019-12-20 CN CN201980092788.4A patent/CN113661246A/zh active Pending
- 2019-12-20 CN CN201980091966.1A patent/CN113454231A/zh active Pending
- 2019-12-20 WO PCT/CA2019/051898 patent/WO2020124273A1/en not_active Ceased
- 2019-12-20 EP EP19899693.6A patent/EP3898998A4/en not_active Withdrawn
- 2019-12-20 BR BR112021012078-5A patent/BR112021012078A2/pt not_active Application Discontinuation
- 2019-12-20 JP JP2021535804A patent/JP2022514420A/ja active Pending
- 2019-12-20 CA CA3124301A patent/CA3124301A1/en active Pending
- 2019-12-20 JP JP2021535833A patent/JP2022516006A/ja active Pending
- 2019-12-20 PE PE2021000922A patent/PE20212307A1/es unknown
- 2019-12-20 AU AU2019410148A patent/AU2019410148A1/en not_active Abandoned
- 2019-12-20 BR BR112021011730-0A patent/BR112021011730A2/pt not_active Application Discontinuation
- 2019-12-20 WO PCT/CA2019/051899 patent/WO2020124274A1/en not_active Ceased
- 2019-12-20 US US17/415,575 patent/US20220056480A1/en not_active Abandoned
- 2019-12-20 US US17/415,606 patent/US20220380799A1/en not_active Abandoned
- 2019-12-20 SG SG11202106460XA patent/SG11202106460XA/en unknown
- 2019-12-20 KR KR1020217022871A patent/KR20210132002A/ko not_active Ceased
- 2019-12-20 MX MX2021007439A patent/MX2021007439A/es unknown
- 2019-12-20 CA CA3124287A patent/CA3124287A1/en active Pending
-
2021
- 2021-06-17 PH PH12021551436A patent/PH12021551436A1/en unknown
- 2021-06-18 CL CL2021001646A patent/CL2021001646A1/es unknown
- 2021-06-19 IL IL284180A patent/IL284180A/en unknown
- 2021-06-20 IL IL284188A patent/IL284188A/en unknown
- 2021-07-16 CO CONC2021/0009354A patent/CO2021009354A2/es unknown
- 2021-07-20 EC ECSENADI202153474A patent/ECSP21053474A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022514420A5 (enExample) | ||
| JP7413338B2 (ja) | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 | |
| JP2022516006A5 (enExample) | ||
| CN105121474B9 (zh) | 融合免疫调节蛋白及其制备方法 | |
| JP6983511B2 (ja) | 脳中の転移乳癌および他の癌を処置するための方法および組成物 | |
| JP7438552B2 (ja) | 注射用医薬品、注射用調製物、および注射用医薬品の製造における使用 | |
| UA129329C2 (uk) | ЗЛИТІ БІЛКИ FLT3L-Fc | |
| JP2023510651A (ja) | 修飾された免疫細胞及びその使用 | |
| JP2021533789A5 (enExample) | ||
| CN111511911A (zh) | 表达特异性地识别人间皮素的细胞表面分子、il-7和ccl19的免疫活性细胞 | |
| CN110357952B (zh) | 识别人乳头瘤病毒hpv16-e7抗原的tcr | |
| WO2019080537A1 (zh) | 包含溶瘤病毒和car-nk细胞的治疗剂及应用、药盒、治疗肿瘤和/或癌症的方法 | |
| CN108085340A (zh) | 一种同时表达靶向cd19和cd20的car与pd1-cd28嵌合受体的慢病毒载体 | |
| JP2021530971A5 (enExample) | ||
| US20210077554A1 (en) | Methods of Neoplasm Treatment Utilizing Complementary Oncolytic Viruses and CAR T-Cells | |
| WO2020067085A1 (ja) | 腫瘍溶解性ワクシニアウイルスと免疫チェックポイント阻害剤との併用によるがん療法並びにこれに用いるための医薬組成物及び組合せ医薬 | |
| Terazaki et al. | An optimal therapeutic expression level is crucial for suicide gene therapy for hepatic metastatic cancer in mice | |
| JP2024528052A5 (enExample) | ||
| CN112996909A (zh) | 表达pd-1结合蛋白的溶瘤病毒及其应用 | |
| Egle et al. | Expression of Apo‐1/Fas (CD95), Bcl‐2, Bax and Bcl‐x in myeloma cell lines: relationship between responsiveness to anti‐Fas mab and p53 functional status | |
| EP3741845B1 (en) | Recombinant vaccinia virus and pharmaceutical composition comprising same | |
| WO2022148736A1 (en) | Vectorization of muc1 t cell engager | |
| CN103212077B (zh) | Erbin抑制剂在制备抗肿瘤药物中的应用 | |
| CA2532460A1 (en) | Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof | |
| CN111499766B (zh) | 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用 |